Scientists are developing therapies to eliminate chemotherapy-induced senescent 'zombie' cells, which may fuel inflammation and cancer relapse. These approaches include repurposing existing cancer ...
A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure. This is an ASCO Meeting Abstract from the 2023 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results